Drug Topics e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Drug Topics e-News
|
|
|
|
 |
 |
| Newest: Osteoporosis update |
| For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here |
|
|
|
Survey
Last month's survey results:
To reduce 30-day readmission rates for Medicare beneficiaries, our health system:
* Uses pharmacists' MTM skills in hospital-to-home transitions. 5%
* Plans to use pharmacists' MTM in hospital-to-home transitions within 6 months. 0%
* Plans to use pharmacists' MTM skills in hospital-to-home transitions within 12 months. 22%
* Has no plans in place to use pharmacists' MTM skills in hospital-to-home transitions. 73%
|
|
This month we would like to know...
The American College of Chest Physicians recommends immediate use of anticoagulants after major orthopedic replacement surgery and extended use post-discharge (at least 10 days for knee replacement and up to 35 days for hip replacement) to help reduce such risks as DVT and pulmonary embolism. Does your health system follow these guidelines?
|
|
|
The American Society of Health-System Pharmacists and the Institute for Safe Medication Practices issued a medication alert about colistimethate last week. Read full article. |
 |
|
|
 |
A monthly review of the
peer-reviewed literature by
Drug Topics' Editorial Advisor
Anna D. Garrett, PharmD, BCPS. Anna Garrett is manager, Outpatient Clinical Pharmacy Programs, Mission Hospital, Asheville, N.C.
|
Risk of recurrent VTE higher in men.
Read full article.
|
FDA has announced more conservative dosing recommendations for erythropoiesis-stimulating agents when they are used to treat anemia in patients with chronic kidney disease because of the increased risks of cardiovascular events such as stroke, thrombosis, and death. Read full article. |
|
FDA has approved rivaroxaban tablets (Xarelto, Janssen Pharmaceuticals), a novel, once-daily, oral anticoagulant for the prevention of deep vein thrombosis that may lead to a pulmonary embolism (PE) in people undergoing knee- or hip-replacement surgery. Xarelto is the only new oral anticoagulant approved for this indication. Read full article. |
|
An FDA advisory panel recommended in late June that Avastin should not be used to treat breast cancer. Read full article. |
|
A broad literature review has evaluated treatment options available to reduce pain and improve physical function and quality of life in patients with painful diabetic neuropathy, and new guidelines were published online May 17 in Neurology and presented at the American Academy of Neurology Annual Meeting. Read full article. |
 |
Meetings and Events
July 22-25, 2011 NPhA Annual Convention
Atlanta
Contact:
107 Kilmayne Drive, Suite C
Cary, NC 27511
Phone: 404-262-3344
Fax: 404-262-8689
August 27-30, 2011 NACDS Pharmacy & Technology Conference
Boston
Contact:
P.O. Box 34814
Alexandria, VA 22334-0814
703-683-5678
October 6-7, 2011 NCPA Diabetes Accreditation
Standards-Practical Applications (DASPA)
Nashville, TN
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447
November 29, 2011 NACDS Foundation
13th Annual Dinner
New York, NY
Contact:
Jennifer Sargeant, Manager,
Foundation Programs and Education, NACDS
703-837-4224
|
|
|
|
| Contact Us |
Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
